3D MEDICINES (01244.HK): Envafolimab Moves to Regular Approval
NewTimeSpace News: On 18 November 2026, 3D Medicines Inc. (stock code: 01244) announced that the NMPA approved on 17 November 2026 the supplemental application for 恩維達® (Envafolimab Injection) to transition from conditional approval to regular approval as a domestically produced drug, under notice of approval No. 2026B08210.
Envafolimab is a recombinant humanised single-domain antibody against programmed death ligand 1 fused with an Fc region. It was independently developed by Alphamab Oncology (stock code: 09966) and has been co-developed with the Company since 2016. In March 2020, Jiangsu Alphamab, 3D Medicines and Jiangsu Simcere entered into a cooperation agreement granting Jiangsu Simcere the exclusive marketing rights for Envafolimab in oncology indications in mainland China.
In January 2024, the Company and Alphamab entered into a licence agreement granting Glenmark exclusive rights and sublicences to develop and commercialise Envafolimab for oncology indications in India, Asia-Pacific excluding Singapore, Thailand and Malaysia, the Middle East and Africa, Russia, CIS countries and Latin America. Envafolimab, the world's first subcutaneous PD-L1 inhibitor, was approved in China in November 2021 for adults with unresectable or metastatic MSI-H or dMMR advanced solid tumours.
Pursuant to Rule 18A.05, the Company cautioned that it may not be able to successfully develop and/or market Envafolimab for indications other than the approved previously treated MSI-H/dMMR advanced solid tumours.
- 3D MEDICINES (01244.HK): 3D189 Hits REGAL Endpoint, Death Risk -41%
- 3D MEDICINES (01244.HK): 3D189/GPS Phase 3 REGAL Hits Pre-specified 80 Events
- 3D MEDICINES (01244.HK): arbitration award against SELLAS Life Sciences fully received and executed, approximately HKD 7.98 million
- Autonomous Driving Concept Stocks Insight | XPENG-W (09868.HK) Posts Q3 Revenue and Delivery Growth, Secures Guangzhou Citywide L4 Robotaxi Demonstration Operation Qualification
- Autonomous Driving Concept Stocks Insight | XPENG-W (09868.HK) Edged Lower, XPeng GX, G9L and Other Models Launched for Sales in 11 Middle Eastern and African Countries